Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neonatal Hypoglycemia Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Enhanced Recovery After Surgery (ERAS) for Cesarean Section on Neonatal Blood Glucose

NCT05081804
View directory record Official record
Conditions
Enhanced Recovery After Surgery, Cesarean Section
Interventions
Carbohydrate Preoperative Drink
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Female only
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Jul 22, 2026, 11:17 PM EDT
Completed No phase listed Observational

Neurodevelopment of Hypoglycemic Neonates

NCT04875624
View directory record Official record
Conditions
Neonatal Hypoglycemia, Neurodevelopmental Disorders
Interventions
Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4)
Diagnostic Test
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Months to 24 Months
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

NCT04538989
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4
Drug
Lead sponsor
Rezolute
Other
Eligibility
2 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 22, 2026, 11:17 PM EDT
Recruiting No phase listed Observational

Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation

NCT02089789
View directory record Official record
Conditions
Congenital Disorders of Glycosylation
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 11:17 PM EDT
Available No phase listed Expanded access

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

NCT01916148
View directory record Official record
Conditions
Congenital Hyperinsulinism (CHI), Beckwith-Wiedemann Syndrome, Insulinoma
Interventions
18F-DOPA
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 11:17 PM EDT
Completed Phase 4 Interventional

Continuous Glucose Monitoring and Preterm Infants

NCT02583776
View directory record Official record
Conditions
Infant, Very Low Birth Weight, Neonatal Hypoglycemia
Interventions
Unblinded - CGM, Blinded - CGM
Device
Lead sponsor
University Hospital Padova
Other
Eligibility
2 Hours to 2 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jul 22, 2026, 11:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Donor Human Milk Supplementation for the Treatment of Hypoglycemia in the Breastfed Infant

NCT04030312
View directory record Official record
Conditions
Neonatal Hypoglycemia
Interventions
Bottle Supplementation--Commercially-Sterilized Donor Human Milk, Bottle Supplementation--Standard Infant Formula
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
1 Minute to 72 Hours
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 22, 2026, 11:17 PM EDT
Terminated Not applicable Interventional Results available

Efficacy of Continuous Glucose Monitoring in Neonates With Hypoglycemia

NCT02300285
View directory record Official record
Conditions
Hypoglycemia, Newborn Morbidity
Interventions
Continuous Glucose Monitoring
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 60 Days
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 22, 2026, 11:17 PM EDT
Active, not recruiting Not applicable Interventional

Intrapartum Glucose Control and Risk of Neonatal Hypoglycemia

NCT06643351
View directory record Official record
Conditions
Gestational Diabetes Mellitus in Pregnancy, Pregestational Diabetes Mellitus, Neonatal Hypoglycemia
Interventions
Standard Intrapartum Glucose Target Range, Liberalized Intrapartum Glucose Target Range
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 11:17 PM EDT
Completed Phase 1 Interventional

Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

NCT03103009
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia
Interventions
Pasireotide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Jul 22, 2026, 11:17 PM EDT
Completed Phase 2Phase 3 Interventional

Dextrose Gel Does Not Prevent Neonatal Hypoglycemia

NCT02523222
View directory record Official record
Conditions
Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia, Intrauterine Growth Restriction, Complication of Prematurity, Neonatal Hypoglycemia
Interventions
40% Dextrose gel
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Hours to 1 Hour
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 22, 2026, 11:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Continuous Glucose Monitoring in Neonatal Hyperinsulinism

NCT06363929
View directory record Official record
Conditions
Hyperinsulinism, Hypoglycemia Neonatal
Interventions
Dexcom G6 continuous glucose monitor
Device
Lead sponsor
MemorialCare Health System
Other
Eligibility
24 Hours to 3 Months
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 11:17 PM EDT
Recruiting Phase 1 Interventional

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

NCT02021604
View directory record Official record
Conditions
Congenital Hyperinsulinism, Insulinoma
Interventions
Fluorodopa F 18
Drug
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
Up to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Jul 22, 2026, 11:17 PM EDT
Completed Phase 2 Interventional

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

NCT02604485
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Cohort 1, Cohort 2, Cohort 3, Cohort 4
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Jul 22, 2026, 11:17 PM EDT
Completed Phase 2 Interventional

Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

NCT03770637
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia
Interventions
Glucagon RTU, Placebo
Drug · Other
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Jul 22, 2026, 11:17 PM EDT
Active, not recruiting Phase 3 Interventional

RZ358 Treatment for Congenital Hyperinsulinism

NCT06208215
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC
Drug
Lead sponsor
Rezolute
Other
Eligibility
3 Months to 45 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

Studies of Elevated Parathyroid Activity

NCT00001277
View directory record Official record
Conditions
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
Interventions
68Ga-Dotatate, 18F-DOPA
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months and older
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jul 22, 2026, 11:17 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Late Preterm Corticosteroids and Neonatal Hypoglycemia

NCT04869709
View directory record Official record
Conditions
Neonatal Hypoglycemia, Prematurity
Interventions
Betamethasone Sodium Phosphate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 22, 2026, 11:17 PM EDT
Recruiting Not applicable Interventional

Continuous Glucose Monitoring in At-Risk Newborns

NCT04386005
View directory record Official record
Conditions
Neonatal Hypoglycemia
Interventions
Continuous Glucose Monitoring Device
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Minute to 2 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia

NCT01468454
View directory record Official record
Conditions
Congenital Hyperinsulinism (CHI), Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Interventions
18 F-DOPA
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Jul 22, 2026, 11:17 PM EDT
Active, not recruiting Phase 3 Interventional

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT03941236
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
dasiglucagon
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
5 Weeks to 13 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 11:17 PM EDT
Terminated No phase listed Observational

Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III

NCT05196165
View directory record Official record
Conditions
Glycogen Storage Disease Type III
Interventions
No Intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
1 Year and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Jul 22, 2026, 11:17 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk

NCT03246243
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy, Hypoglycemia, Neonatal Abstinence Syndrome
Interventions
nfant feeding solution
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Jul 22, 2026, 11:17 PM EDT
Terminated No phase listed Observational

Clinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease Population

NCT02338817
View directory record Official record
Conditions
Glycogen Storage Disease
Interventions
Diabetes Sentry
Device
Lead sponsor
University of Florida
Other
Eligibility
Up to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Jul 22, 2026, 11:17 PM EDT